ArticleAMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science2016
A Use Case to Support Precision Medicine for Frequently Hospitalized Older Adults with Polypharmacy.
Article in AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Preferences for pharmacogenomic testing in polypharmacy patients: a discrete choice experiment.Personalized medicine · 2022Article
- Drug-Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PINPharmaceuticals (Basel, Switzerland) · 2021Article
- Pharmacogenomic Approaches for Automated Medication Risk Assessment in People with Polypharmacy.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2018Article
- Integrating clinical decision support systems for pharmacogenomic testing into clinical routine - a scoping review of designs of user-system interactions in recent system development.BMC medical informatics and decision making · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polypharmacy in older adults results in multiple negative clinical consequences including increased risk of hospital readmissions. Precision medicine may provide tools to optimize complex medication regimens however its potential in older adults with polypharmacy is unknown. We carried out pharmacogenetic testing in an older adult with multiple chronic conditions and polypharmacy who was concerned about frequent readmissions despite receiving guideline-concordant care and being adherent to medication regimen. The testing identified patients' CYP2D6 rapid metabolizer status. This may have resulted in decreased exposure to Carvedilol which was primary drug for CHF management in this patient. Additional nine drug-drug interactions were identified during personalized drug regimen review. We concluded that, though precision medicine has enormous potential in older adults with polypharmacy, the complexity of pharmacogenetic information requires innovative informatics solutions to support optimal workflows, decision support, and medication optimization and management in order to fully utilize its potential in routine clinical care.
Identifiers
27570642PMC5001756What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.